Glucagon-like peptide-1 (GLP-1) agonists were originally developed for treating type 2 diabetes, but they have also demonstrated significant weight reduction benefits, consistently observed in clinical trials and studies. Here, GLP1R is linked to type 2 diabetes mellitus.